First Manhattan’s Cymabay Therapeutics CBAY Stock Holding History

First Manhattan’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$218K	–	1571
2023 Q1	$218K	Hold	25,000	–	–	﹤0.01%	664
2022 Q4	$157K	Hold	25,000	–	–	﹤0.01%	743
2022 Q3	$87K	Hold	25,000	–	–	﹤0.01%	843
2022 Q2	$73K	Hold	25,000	–	–	﹤0.01%	903
2022 Q1	$77K	Hold	25,000	–	–	﹤0.01%	928
2021 Q4	$84K	Hold	25,000	–	–	﹤0.01%	899
2021 Q3	$91K	Hold	25,000	–	–	﹤0.01%	880
2021 Q2	$109K	Hold	25,000	–	–	﹤0.01%	846
2021 Q1	$113K	Hold	25,000	–	–	﹤0.01%	808
2020 Q4	$143K	Hold	25,000	–	–	﹤0.01%	729
2020 Q3	$181K	Buy	25,000 +22,500	+900%	+$120K	﹤0.01%	669
2020 Q2	$8K	Buy	+2,500	New	+$7.21K	﹤0.01%	1200

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

First Manhattan's CBAY Position: Q2 2023 in Review

First Manhattan sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 25,000 shares — an estimated $218K sold.

First Manhattan first reported a position in CBAY in Q2 2020 and held it in 12 quarters. The position peaked at $218K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

First Manhattan reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
First Manhattan sold 25,000 Cymabay Therapeutics shares in Q2 2023, an estimated $218K.
First Manhattan first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 12 quarters.
First Manhattan's Cymabay Therapeutics position peaked at $218K in Q1 2023.
151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.